TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
EMPOWER YOURSELF WITH KNOWLEDGE
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
EHE Biobank: Patients Powering Research
You didn’t choose to have cancer, but you can make a difference in how the world fights it. Join Patty Cogswell, EHE Biobank Coordinator, in an informal, interactive conversation on the questions, challenges and benefits of donating tissue and fluids to the EHE Biobank. Learn how YOUR contributions can directly power research and help us […]
Who am I now? Integrating the cancer identity into the self.
You are invited to the EHE Community Connections session on Saturday, May 14th, at 11:00 AM Eastern Time (US). Dr. Tamara Vesel and Dr. Maeve Baechler will be facilitating the discussion and exploring questions like Why is it important to contemplate on identify after the cancer diagnosis. How does the issue of identity relates to symptoms during cancer treatment? Ups and down of resisting versus incorporating cancer diagnosis into one’s life.
Scanxiety
What is scanxiety? Scanxiety describes the apprehension felt by people with cancer as they wait for their next scan. It’s a form of anticipatory anxiety. Scans are like emotional roulette. You’re trying really hard not to worry about the unknown, but your body has other plans. Recognizing the Signs of Scanxiety Symptoms of scanxiety vary […]
Planned Ikena Oncology Clinical Trial to Include EHE Patients
The planned Phase 1 clinical trial includes patients with tumor types with a high frequency of Hippo pathway alterations, including NF2-deficient malignant mesothelioma and some soft tissue sarcomas with YAP/TAZ genetic fusions, including Epithelioid Hemangioendothelioma (EHE), a rare form of soft tissue sarcoma that has a significant unmet medical need with no currently approved therapy […]
The Pledge: Edition 27, Q4 – Oct-Dec, 2021
Together, the US, UK, and Australia EHE foundations team up to strengthen the force against EHE. This group provides a quarterly update, which is led by the UK and includes research news, patient and fundraising stories, and much more! Click here to view the most recent edition of our online EHE newsletter, The Pledge.
Stronger Together on Giving Tuesday, November 30th
As the season of giving and gratefulness is upon us, we want to thank you for being a part of The EHE Foundation family. We appreciate you following our progress and investing in our passion: discovering effective treatments and a cure for EHE. We are thankful for our supporters, partners, and volunteers who make our […]
The Pledge: Edition 43, Q4 – October-December, 2025
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content, including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.
Understanding Quality of Life for People Living With EHE
The European Organisation of Research and Treatment of Cancer (EORTC) is conducting research to better understand health-related quality of life (HRQoL) concerns among people living with rare cancers. Recently, researchers analyzed results from a group of 31 people with EHE from 11 different countries who participated in the study. The findings showed that pain–and the […]
Exploring Eribulin as a Potential Treatment Option for EHE
Prior research has shown that a class of medications called microtubule inhibitors may be effective at controlling the growth of EHE tumors. Recently, researchers conducted a phase 2 study to test whether the microtubule inhibitor eribulin is a safe and effective way to treat patients whose tumors continued to grow after prior treatment. Six (6) […]